[Federal Register Volume 62, Number 194 (Tuesday, October 7, 1997)]
[Notices]
[Page 52342]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-26499]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Scientific Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) has made a final finding of scientific misconduct in the
following case:
Xiaomin Shang, Ph.D., University of Texas Southwestern Medical
Center: Based upon a report from the University of Texas Southwestern
Medical Center, information obtained by the Office of Research
Integrity (ORI) during its oversight review, and Dr. Shang's own
admission, ORI found that Dr. Shang, a former postdoctoral fellow
student in the Department of Obstetrics and Gynecology, University of
Texas Southwestern Medical Center, engaged in scientific misconduct
arising out of certain biomedical research supported by a training
grant from the National Institute of Child Health and Human Development
(NICHD), National Institutes of Health (NIH).
Specifically, Dr. Shang fabricated a chemiluminescent film of a
Western blot by using a physical mask to alter the prior results
showing lack of antibody specificity to a human steroid metabolizing
isozyme, rather than replicating an experiment as requested by his
mentor. The fabricated data were not published.
Dr. Shang has accepted the ORI finding and has entered into a
Voluntary Exclusion Agreement with ORI in which he has voluntarily
agreed, for the three (3) year period beginning September 29, 1997:
(1) To exclude himself from serving in any advisory capacity to the
Public Health Service (PHS), including but not limited to service on
any PHS advisory committee, board, and/or peer review committee, or as
a consultant; and
(2) That any institution that submits an application for PHS
support for a research project on which Dr. Shang's participation is
proposed or which uses him in any capacity on PHS supported research or
that submits a report of PHS-funded research in which he is involved
must concurrently submit a plan for supervision of his duties to the
funding agency for approval. The supervisory plan must be designed to
ensure the scientific integrity of Dr. Shang's research contribution.
The institution also must submit a copy of the supervisory plan to ORI.
No scientific publications were required to be corrected as part of
this Agreement.
FOR FURTHER INFORMATION CONTACT: Acting Director, Division of Research
Investigations, Office of Research Integrity, 5515 Security Lane, Suite
700, Rockville, MD 20852, (301) 443-5330.
Chris B. Pascal,
Acting Director, Office of Research Integrity.
[FR Doc. 97-26499 Filed 10-6-97; 8:45 am]
BILLING CODE 4160-17-P
